(CercleFinance.com) – Valneva announced on Thursday that its chikungunya vaccine project would be presented at the World Vaccine Congress to be held next week in Washington.
On Wednesday April 5, Susanne Eder-Lingelbach, its vice-president in charge of clinical development, will present the clinical results of the single-injection vaccine candidate against chikungunya.
For the record, a regulatory review process is currently underway with the American health authority, the Food and Drug Administration (FDA).
If approved, this product could become the world’s first available chikungunya vaccine.
The day before, Juan Carlos Jaramillo, the group’s medical director, will lead a round table on the opportunities and difficulties encountered in the development of a vaccine against the Zika virus.
Valneva recalls having successfully developed, until the end of Phase 1, an inactivated whole-virus vaccine candidate against the Zika virus.
The company is currently evaluating the possibility of resuming clinical development of this candidate later this year or early next year.
Pending these two meetings, the Valneva title showed an increase of 2.5% Thursday morning on the Paris Stock Exchange, against an increase of around 1% for the SBF 120 index.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
